ERBB2 and breast carcinoma: In a phase I trial of AZD9496, an oral selective ER degrader, single-cell CTC analysis in patients with advanced ER-POS/HER2-negative advanced breast cancer at serial time points was performed, using tandem CellSearch® /DEPArrayTM technologies and targeted single-cell DNA next-generation sequencing.